Sofgen Pharma S.A. filed an initial Form 3 for Chief Commercial Officer Luis Alberto Palacios. This filing identifies him as an officer and reporting person for Sofgen Pharma’s securities but does not report any transactions or derivative positions. It establishes his status for future ownership disclosures.
Sofgen Pharma S.A. director Alberto Eguiguren filed a Form 3 related to the company. The filing shows no reported buy, sell, acquisition, or disposition transactions, and no derivative positions, indicating a baseline insider ownership report without trading activity in this filing.
Sofgen Pharma S.A. filed an initial ownership report for director Carlos Garcia Iragorri. This Form 3 shows his status as a director of the company but does not list any share transactions or derivative positions. The summarized data indicate no reported purchases, sales, exercises, gifts, or other changes in ownership at this time.
Sofgen Pharma S.A. director Daniel Augusto Bernal Jaramillo filed an initial Form 3, which is a mandatory disclosure of insider status at the company. The filing reports no transactions or derivative positions, serving only to register his status as a reporting person.
Sofgen Pharma S.A. director and 10% owner Fernando Sebastian Moreira Muniz filed an initial statement of beneficial ownership. The filing reports indirect holdings through Becaril S.A., which Becaril beneficially owns 305,309,149 Ordinary Shares of Sofgen Pharma and a warrant to purchase 19,800,411 Ordinary Shares with an exercise price of $0.0631 per share expiring on April 9, 2035. These entries reflect existing positions rather than new market transactions.
Sofgen Pharma S.A. director Romero Camacho Carlos has filed an initial statement of beneficial ownership on Form 3 for the company’s shares. The available data show no reported buy, sell, or other insider transactions and no derivative positions in this filing.